The newly launched report by Stratview Research, titled - Hereditary Angioedema Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth Opportunity: 2021-2026 has been bifurcated By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Intravenous, Subcutaneous Injection, Oral), End-Use (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and Region - COVID-19 Impact Analysis and Forecast to 2026.
According to the report, The Hereditary Angioedema Market is projected to grow from USD 1.9 billion in 2020 to USD 2.8 billion by 2026 at a CAGR of around 7.2% during the forecast period.
How does this report help?
Reports published by Stratview Research helps the users in several ways. The user can –
- Gain a deeper understanding of the market and the impact of Covid-19 on the market.
- Get rigorous analysis and progressive insights into the market across the globe.
- Assess current and future market trends, and challenges of the market.
- Gain a comprehensive view on the growth strategies of the key players.
- Get updates related to recent changes, M&As, new product launches and many such news related to the market, and even more.
Market Segmentation Analysis -
By end-use, the hereditary angioedema market has been bifurcated into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment can be attributed to the convenience and availability of drugs.
By region, the North American market accounted for the largest market share in 2020 and is projected to grow at a robust CAGR during the review period. This can be attributed to expanding geriatric populace and increasing investment in R&D activities to develop new drugs coupled with the presence of key market players such as Shire plc (US) and BioCryst Pharmaceuticals, Inc. (US). The market growth in Asia-Pacific is expected to be driven by an increasing number of people having hereditary angioedema disease.
Wish to get a free sample report? Click Here: https://www.stratviewresearch.com/Request-Sample/2378/Hereditary-Angioedema-Market.html#form
The following are the key players in the market-
Pharming Group NV (Netherlands)
Shire plc (US)
CSL Limited (Australia)
iBio Inc. (US)
BioCryst Pharmaceuticals, Inc. (US)
Ionis Pharmaceuticals (US)
Sanofi S.A. (France)
Attune Pharmaceuticals, Inc. (US)
Adverum Biotechnologies, Inc. (US).
Stratview Research's reports are the result of a thorough analysis that combines thorough secondary, and primary interviews with industry leaders, and confirmation using unique internal database and statistical methods. More than 1,000 verified secondary sources, such as annual reports from companies, press releases, fact books, journals, white papers, and blogs are reviewed and analysed.
About Stratview Research -
Stratview Research is one of the leading providers of custom and syndicated market research reports. We also offer services like Sourcing, Market Entry Strategy, Target Screening, Voice of Market Study, and much more. In case of any requirement related to market assessment, competitive benchmarking, and others, please send your inquiry to the team.
Email at - email@example.com
Connect with the analysts at - +1-313-307-4176.